Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ13404 Monotherapy in Advanced or Metastatic NSCLC
NCT05662670Phase 2Terminated
- Sponsor
- Suzhou Junjing BioSciences
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of wj13404 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Junjing BioSciences. Primary endpoints: Adverse Events up to 1 year, Objective Response Rate up to 3 years and 1 more. Started Oct 2022; status: terminated.
02
Drugs
wj13404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05662670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662670.